The P300/CBP-associating factor (PCAF), a histone acetyltransferase, is involved in metabolic and pathogenic diseases, particularly of the liver. The effects of PCAF on fine-tuning liver diseases are extremely complex and vary according to different pathological conditions. This enzyme has dichotomous functions, depending on differently modified sites, which regulate the activities of various enzymes, metabolic functions, and gene expression. Here, we summarize the most recent findings on the functions and targets of PCAF in various metabolic and immunological processes in the liver and review these new discoveries and models of PCAF biology in three areas: hepatic metabolic syndrome, inflammatory disease, and cancer. Finally, we discuss the potential implications of these findings for therapeutic interventions in liver diseases.
| INTRODUCTION
Obesity, type 2 diabetes mellitus (T2DM), and other disturbances of chronic metabolic syndrome are now worldwide health problems. [1] [2] [3] There is a parallel trend of the incidence and prevalence of immune diseases and tumorigenesis. 4, 5 The liver, the largest visceral organ in the body, has been intimately associated with various diseases including chronic metabolic syndrome, inflammation, and cancer. [6] [7] [8] [9] Under pathological conditions, the activation of immune cells and inflammatory pathways lead to liver complications, including damage to hepatic metabolic homeostasis and a cluster of interrelated metabolic risk factors such as raised fasting glucose, central obesity, dyslipoproteinaemia, and hypertension. [10] [11] [12] [13] In addition, the damage of hepatic metabolic homeostasis and inflammatory disease has gained increasing attention for its relationship with end-stage liver disease:
primary liver cancer and hepatocellular carcinoma (HCC). [14] [15] [16] Several transcription factors are concurrently critical mediators in the regulation of biological processes, especially under illness stress. 17, 18 These transcription factors are subjected to posttranslational modifications (PTMs) that affect their activity, stability, intracellular distribution, and interaction with other proteins. [19] [20] [21] [22] [23] During the past decades, the inventory of acetylation, demonstrated by the number of modification sites, is fast catching up with other major PTMs, such as phosphorylation and ubiquitylation, highlighting the regulatory potential of this modification at the proteomics scale. 24 Recent studies have reported that overall cellular metabolism can be regulated through acetylation. [25] [26] [27] [28] Predictably, as a pivotal metabolic organ, the liver is largely subjected to lysine acetylation, which occurs in most of the metabolic enzymes in human liver cells involved in glycolysis, tricarboxylic acid (TCA) and urea cycles, and fatty acid and glycogen metabolism. [29] [30] [31] [32] [33] The acetylation status of these enzymes may alter their activities in order to respond to any changes in metabolic pathological demands. 34, 35 The P300/CBP-associating factor (PCAF) is a histone acetyltransferase (HAT) that primarily acetylates H3 histones and has a strong association with tumour initiation and progression, and it is similar to other HAT family member-GCN5 eukaryotes. 36 Using various nutri-PCAF-acetylated lysine sites has rapidly expanded. An emergent theory indicates that PCAF is also involved in multiple hepatic metabolic and pathogenic diseases such as metabolic syndrome, inflammation, apoptosis, injury, and cancer. For example, PCAF can acetylate nonhistone proteins, including, phosphoglycerate kinase 1 (PGK1) (K323), ATP-citrate lyase (ACLY) (K540, K546, and K554), Peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC1-α) (K328 and K450), forkhead box P3 (FOXP3), and p53, etc. [37] [38] [39] [40] [41] Additionally, increasing evidence demonstrates that PCAF is not only a HAT but also shows other effects such as ubiquitination. 42 This review primarily focuses on the different mechanisms by which PCAF fine-tunes hepatic metabolic syndrome, inflammatory disease, and tumour growth.
| PCAF IN HEPATIC METABOLIC SYNDROME
As an associated factor of p300/CBP, PCAF and has been identified based on its activity in histone acetylation and is implicated in various cellular processes including proliferation and apoptosis. 43, 44 More recently, a growing body of evidence has implicated PCAF in hepatic metabolic homeostasis, including lipogenesis, fatty acid oxidation, gluconeogenesis, and the regulation of insulin action, suggesting that PCAF activity may ensure the coordinated regulation of several distinct metabolic functions in the liver. Further study of PCAF will likely contribute to the development of treatments for hepatic metabolic syndrome and other nonalcoholic fatty liver diseases.
| Hepatic lipid metabolism

| Hepatic de novo lipogenesis and hyperlipidaemia
Hyperlipidaemia is a prevalent disease and a major component of metabolic syndromes. 45, 46 In a physiological study, using a diabetic pregnant rat model, Abraham and colleagues showed that increased hepatic de novo lipogenesis directly contributes to hyperglycaemia and hyperlipidaemia. 47 Apolipoprotein apoC-III is important in lipogenesis and triglyceride (TG) metabolism. Hepatic apoC-III production is subject to insulin inhibition, and is effectively up-regulated by forkhead box O1 (FoxO1). A previous study on mice demonstrated that FoxO1 deregulation is associated with insulin deficiency or insulin resistance. Elevated FoxO1 production in the liver augments hepatic apoC-III expression, resulting in increased plasma TG levels and impaired fat tolerance. 48 In addition, transgenic mice expressing a constitutively nuclear FoxO1 allele directly exhibited hypertriglyceridaemia. 48 phosphorylation in response to feeding/insulin via preferential interaction with PCAF. 55 Thus, the phosphorylation-dependent acetylation of USF-1 by PCAF and DNA-PK functions as a dynamic molecular switch in sensing the nutritional transition from fasting to feeding. Such a multistep switch provides a mechanism to fine-tune the transcription of lipogenic genes in response to different nutritional states ( Figure 1A ).
| Nonalcoholic fatty liver disease and endoplasmic reticulum stress
The long-term state of hyperlipidaemia leads to liver pathologies referred to as nonalcoholic fatty liver disease (NAFLD), which represents a large spectrum of diseases, including hepatic steatosis, fatty liver, and nonalcoholic steato hepatitis (NASH). [56] [57] [58] [59] Deciphering the specific activities and substrates of PCAF mediating its different physiological functions in NAFLD has become an important area of research, as these functions may not only be limited to acetylation.
According to one previous study, Lew et al showed that PCAF mediates X-box-binding protein1 (XBP-1)-dependent transcription through interaction with XBP-1S. XBP-1S is the necessary transcriptional activator of unfolded protein response, which is triggered when the endoplasmic reticulum (ER) is under stress. 60 ER stress has been closely associated with hepatic steatosis, as hepatic lipid overload has been implicated in the initiation of the chronic ER stress in steatosis. 61, 62 Steatosis is the first step in the progression of NAFLD, and is characterized by lipid accumulation in hepatocytes and is highly prevalent in people with obesity and hyperlipidaemia. 63, 64 The PCAF-induced translation of the spliced XBP1 mRNA generates a very potent form of the XBP1 transcription factor, which in turn increases the expression of ER chaperones and ER-associated degradation under stress. 65 Although the liver only undergoes transient 
| Hepatic glucose homeostasis
| PGC1-α and Foxo1 acetylation in hepatic gluconeogenesis
In 1898, Naunyn coined the term hepatogenous diabetes to describe the coincidence between diabetes and liver glucose disorder, emphasizing the pathological importance of the liver in regulating glucose metabolism. 75 Several transcription factors and co-activators are involved in the nutritional and hormonal control of gluconeogenesis, including PGC-1α and FoxO1.
Accumulating evidence reveals that PGC-1α increases the activity and increases the expression of many proteins involved in fatty acid β-oxidation, the TCA cycle, and the electron transport chain, such as PPARα, and the glucocorticoid receptor. [76] [77] [78] Notably, the adenoviralmediated expression of PGC-1α in the hepatocytes strongly activates the entire programme of gluconeogenesis and increases glucose output. 79 These results robustly demonstrate that PGC-1α is a key transcriptional coactivator in hepatic gluconeogenesis, which is implicated in the onset of type-2 diabetes. It was recently observed that PGC-1α is acetylated and deacetylated by acetyltransferase GCN5 and deacetylase Sirt1, respectively, for regulation of its transcriptional activity in response to nutrients supply. When nutrient availability is high, PGC-1α is acetylated by GCN5. As nutrients are exhausted, sirt1 activity is enhanced and PGC-1α is deacetylated to maintain energy metabolism balance. 80, 81 Intriguingly, another recent finding revealed that PCAF is a pivotal HAT that acetylates PGC-1α
in both fasting and diabetic states, and acetylates K328 and K450 residues in PGC-1α, leading to its proteasomal degradation. 39 Given that the acetylation of FoxO1 at K242 and K245 by PCAF inhibits its transcriptional activity, it is likely that PCAF may modulate gluconeogenesis through additional mechanisms. Studies have
shown that S-phase kinase-associated protein 2 (Skp2), which is involved in the regulation of glucose metabolism, interacts with ubiquitinases and promotes the degradation of FoxO1 through the Aktspecific phosphorylation of Serine 256, thus suppressing the effects of this protein. 82 This result suggests that the ubiquitination and degradation of FoxO1 by Skp2 may contribute to the onset of insulin resistance and diabetes. As the acetylation of FoxO1 by PCAF F I G U R E 2 Potential contributions of PCAF-induced acetylation to the development of hepatic Glucose homeostasis. A, PGC1-α acetylation and hepatic gluconeogenesis. PCAF acetylate at lysine 328 and 450 residues, leading to its proteasomal degradation and attenuates PGC-1α-driven hepatic gluconeogenesis; (B) PI3K-Akt/PKB signalling pathway and hepatic insulin resistance: ER stress activates TRB3; PTEN and TRB3 are both acetylated by PCAF increasing their activity to inhibit the PI3K-Akt/PKB signalling pathway, therefore, leading to hepatic insulin resistance; (C) FoxO1 activity in diabetes. PCAF might regulate gluconeogenesis through binding and acetylating FoxO1 and decreasing both Pck1 and G6pc gene expression, resulting in decreased gluconeogenesis, therefore mitigating diabetes. PTEN, phosphatase and tensin homologue deleted on chromosome ten; TRB3, tribbles 3; Pck1, phosphoenolpyruvate carboxykinase; G6pc, glucose 6-phosphatase inhibits FoxO1-induced transcription in the nucleus, there is also cooperation between PCAF and Skp2 in modulating FoxO1, thereby regulating glucose metabolism. 49 Additionally, the genes involved in gluconeogenesis, including glucose 6-phosphatase (G6pc) and phosphoenolpyruvate carboxykinase (Pck1), were recently demonstrated as target genes of FoxO1. 83 In an in vivo experiment employing the adenoviral-mediated transfer of a dominant negative FoxO1 into Lepr db/db mice, the reduction in nuclear FoxO1 decreased both Pck1 and G6pc gene expression, reducing gluconeogenesis and fasting blood glucose. 84 Furthermore, antisense oligonucleotides of FoxO1 inhibit Pck1 and G6pc gene expression in primary hepatocytes which were stimulated with glucagons. 85 These observations support the previous finding that FoxO1 increases hepatic gluconeogenesis through G6pc and Pck1 gene expression. Thus, PCAF might inhibit gluconeogenesis through additional mechanisms via the acetylation of FoxO1 ( Figure 2C ).
| PI3k-Akt/Pkb signalling pathway and hepatic insulin resistance
The liver is a significant insulin-sensitive organ in the regulation of glucose homeostasis. 86, 87 Thus, insulin resistance in the liver was suggested as an underlying cause of metabolic syndrome, including hyperglycaemia, dyslipidaemia, and increased inflammatory factors. 
| PCAF IN LIVER INJURY AND MED IATORS OF INFLAMMATION
Metabolism and immunity are closely linked. Long-term hepatic metabolic disorders result in systemic low-grade chronic inflammation of the liver. To a great extent, the inflammatory response contributes to the development of acute and chronic liver diseases. [96] [97] [98] Recently, PCAF was demonstrated to influence various aspects of liver inflammation through multiple mechanisms, thus the targets of PCAF in proinflammatory reaction, oxidative stress, and liver injury will be discussed in this review. responses, a process that may be relevant to the epigenetic finetuning of epithelial inflammatory processes in general ( Figure 3D ).
|
| Liver inflammation and oxidative stress
Oxidative stress and liver inflammation/injury are strongly associated.
It occurs as a consequence of imbalance between the production of reactive oxygen species and the body's ability to detoxify reactive intermediates.
103,104
More recently, Tyrosyl-tRNA synthetase (TyrRS), a member of the 20-enzyme family of aminoacyl-tRNA
synthetases, has been shown to translocate to the nucleus and protect against DNA damage because of oxidative stress, and the nuclear translocation of TyrRS is promoted by lysine acetylation in response to oxidative stress. 105 In addition, PCAF and SIRT1 function as the acetyltransferase and deacetylase of TyrRS, respectively.
Oxidative stress increases the level of PCAF and decreases the level of SIRT1 and deacetylase activity, all of which promote the nuclear translocation of hyperacetylated TyrRS. Furthermore, TyrRS is primarily acetylated on the K244 residue near the nuclear localization signal, and acetylation inhibits the aminoacylation activity of TyrRS. 105 Notably, the acetylation of TyrRS by PCAF may cause hepatocellular DNA damage under oxidative stress, thus leading to immunoreaction in the liver ( Figure 3A ). Figure 3C ). These findings show a novel and unifying mechanism for the effect of acetyltransferases on miRNA transcription and the potential for morphological consequences. Moreover, this epigenetic mechanism will provide a potential therapeutic strategy to treat liver fibrosis.
| Liver injury and hepatic fibrosis
| PCAF IN LIVER CANCER AND TUMOUR
GROWTH
An association between inflammation and cancer has long been suspected. Indeed, pathological changes in the metabolic and physiological status of the liver such as NAFLD, NASH, injury, and cirrhosis, result in the onset of liver cancer, including HCC. 116, 117 Here, we review and discuss recent advances in the elucidation of cellular and molecular alterations, signalling pathways associated with PCAF, and their effects on hepatocarcinogenesis and tumour growth.
| PCAF-induced acetylation and HCC
As one of the end-stage liver diseases, HCC ranks as the third leading cause of cancer mortality worldwide. 118 Recently, with the rise of epigenetics, HCC metastasis and recurrence was demonstrated to involve lysine acetylation, especially, PCAF-induced acetylation.
Mounting evidence over the last 5 years implies different effects of PCAF on HCC. PCAF is likely expressed at low levels in most HCC cell lines. In addition, its overexpression induces HCC cell apoptosis and autophagy. 119 PCAF has also been proposed to act as a metastasis suppressor of HCC by restraining the activity of transcription factor glioma-associated oncogene homologue-1 (Gli1), thus inhibiting the epithelial-to-mesenchymal transition (EMT) of HCC cells. Given that PTEN protein can be acetylated by PCAF, this mechanism can also contribute to the occurrence of HCC. 90 The tumour suppressor activity of PTEN principally exerts its antagonistic effects on the antiapoptotic, proliferative, and hypertrophic activity of PI3K. 125 In cancer biology, PTEN is frequently mutated or deleted in a wide variety of tumours. In patients with HCC, mutations, decreased promoter activity, and decreased PTEN expression are common occurrences. 126 Indeed, the expression of PCAF increases the acetylation of lysine residues (Lys125 and 128)
within the catalytic cleft of PTEN. 90 The acetylation of PTEN Gli1, glioma-associated oncogene homologue-1; Bcl-2, B-cell lymphoma-2; BAX, Bcl-2-Associated X Protein; GAPDH, Glyceraldehyde-3-phosphate dehydrogenase; PKM2, pyruvate kinase M2; PGK1, Phosphoglycerate kinase 1; Ub, ubiquitination important step in progression of NAFLD towards understanding HCC. 127, 128 These results indicate that a PTEN acetylation mechanism supports a correlation between distinct cancer-relevant pathways that are essential to the control of growth factor signalling and gene expression ( Figure 4C ).
| Warburg effect and tumour growth
Almost all cancer cells mainly rely on an aerobic glycolysis pathway to utilize glucose, the so-called "Warburg Effect" first described by Dr.
Otto Warburg. 129, 130 The two enzymes that control the production of ATP during aerobic glycolysis in cancer cells are PGK1 and pyruvate kinase M2 (PKM2). Both enzymes were acetylated by PCAF. 37, 131 Using immunoprecipitation of endogenous proteins and in vitro pulldown assay with recombinant, a study identified and validated that PCAF as the acetyltransferase acetylating PGK1 K323 acetylation in liver cancer, this modification is characterized as an important positive regulation of PGK1 enzymatic activity and its oncogenic function. 37 In addition, they further identified and validated that SIRT7 is the deacetylase of PGK1 at K323. And it can be proposed that PCAFinduced K323 acetylation of PGK1 enhances its activity and promotes cancer cell proliferation and tumorigenesis ( Figure 4D ).
Similarly, the enzyme PKM2 was also associated with PCAF. 131 The K305 site of PKM2 can be acetylated by PCAF, enhancing its association with the heat shock cognate protein 70 (HSC70) thereby promoting its lysosomal-dependent molecular chaperone-mediated autophagy process of degradation. 131 High-glucose concentrations increased the acetylation of PKM2 at Lys305, decreased PKM2 abundance, and increased association of PKM2 with the acetyltransferase PCAF. Ectopic expression of PCAF increased acetylation of PKM2 at K305 and decreased PKM2 activity. The glucose-induced acetylation of PKM2 by PCAF, which inhibits its activity and triggers its autophagic degradation, promotes increased amounts of glycolytic intermediates that enable tumour growth and cell proliferation ( Figure 4D ).
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH), a housekeeping glycolytic enzyme, has also shown to be acetylated by PCAF. 132 Lysing acetylation activates GAPDH, which will alter along with the dynamic changes of external environment, such as glucose concentration. A recent study demonstrated that GAPDH K254 was acetylated by PCAF and deacetylated by HDAC5. Acetylation of GAPDH by PCAF promoted cell proliferation and tumour growth 132 Most enzymes in glycolysis, including GAPDH, are acetylated in the liver, suggesting a positive role for PCAF-induced acetylation of GAPDH in liver tumour growth and providing a potential therapy target for cancer. Furthermore, K117 and K251 are the putative GAPDH residues that could also be acetylated by PCAF. These modifications enable the entry of GAPDH into the nucleus for gene transcription and DNA repair 133 ( Figure 4D ).
Additionally, as a tumour suppressor, p53 has also shown to be acetylated by PCAF in response to DNA damage. 41 CBP/p300 acetylates p53 to achieve full transcriptional activity. This mechanism raised the question of whether PCAF can also acetylate p53 and if so, whether the substrate specificity would be distinct from that of CBP/p300. To address this question, an in vitro study suggested that PCAF and p300 acetylated full-length p53 (p53 FL), and both enzymes had nearly equal acetylation activities. Lysine 320 in p53 is acetylated by PCAF, and PCAF acetylation activates the sequencespecific DNA binding of p53. The acetylation site at K320 is targeted by PCAF and the acetylation at K373 is targeted by p300.
Both p300 and PCAF increase the affinity of p53 to bind its cognate DNA site. 41 These findings suggested that p53 PCAF-induced acetylation is of great importance for DNA damage and cancer (Figure 4E) . As p53 serves as a tumour suppressor protein it might have significant connection to liver cancer. This mechanism could provide us with a new pathway for the treatment of liver cancer.
| CONCLUDIN G DISCUSSION AND PERSPE CTIVE
The (Table 1) .
To date, the molecular events by which PCAF exerts a protective role at the hepatic organelle level, regulating the hyperglycaemia, ER stress to oxidative stress, and Warburg effect are still not fully understood. However, based on this review, it is increas- 
